VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.

VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinase 1 (VRK1) with an IC50 of approximately 150 nM. It also facilitates H4 deacetylation (reducing H4K16 acetylation) and promotes the accumulation of DNA strand breaks while preventing progression of the DNA repair process.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.

CD1530 is a potent and selective agonist of RARγ receptor with Ki values of 150 nM. It is a potent inhibitor of heterotopic ossification (HO) and may be effective against congenital HO, with potential use in research on psoriasis, acne, photoaging, and cancer.

MDL12330A is an inhibitor of adenylyl cyclase that blocks vasopressin-induced short-circuit current (SCC). It also inhibits cAMP phosphodiesterase, which may mask its effect on adenylyl cyclase.

CD1530 is a potent and selective agonist of RARγ receptor with Ki values of 150 nM. It is a potent inhibitor of heterotopic ossification (HO) and may be effective against congenital HO, with potential use in research on psoriasis, acne, photoaging, and cancer.

CD1530 is a potent and selective agonist of RARγ receptor with Ki values of 150 nM. It is a potent inhibitor of heterotopic ossification (HO) and may be effective against congenital HO, with potential use in research on psoriasis, acne, photoaging, and cancer.